This trial is evaluating whether Core Biopsy will improve 3 primary outcomes and 2 secondary outcomes in patients with Breast Carcinoma In Situ. Measurement will happen over the course of Up to 35 days post-treatment.
This trial requires 120 total participants across 1 different treatment group
This trial involves a single treatment. Core Biopsy is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"After surgery, carcinoma, mammary ductal cancer may progress in the vast majority of patients, with more than half experiencing further disease. These patients need new and intense treatment." - Anonymous Online Contributor
"The data are discussed in terms of the cancer stem cell hypothesis, and the evidence given supporting this theory to explain the common occurrence of multiple carcinomas in cases of breast cancer." - Anonymous Online Contributor
"Signs of breast tumors are the changes in the tumor and the skin, as well as some signs of systemic disorders. More detailed knowledge and signs from the whole body, especially the skin, may help the physician diagnose the type of tumor." - Anonymous Online Contributor
"This rare tumour is caused by the precancerous changes of a benign tumour, and is often treated with breast-saving surgery. Although the exact cause of carcinoma, mammary ductal carcinoma is not well understood, many factors may be involved in the development of this tumour. There is no single'single' risk factor (genetic, hormonal, environmental, etc). The development of the carcinoma, mammary ductal tumours is a chronic, but not constant, progression over time. Most cases of carcinoma, mammary ductal are diagnosed at an early stage, when there is a very good chance of cure following surgery and radiotherapy." - Anonymous Online Contributor
"Adenocarcinoma of the breast is treated most often through surgery through a mastectomy or through an alternate option, such as the lumpectomy with negative margins. On the contrary, the majority of women diagnosed with ductal carcinoma report a history of ductal carcinoma in situ (DCIS), with less than 1 percent opting for lumpectomy and less than 40 percent opting for mastectomy if they are diagnosed once the lesion has progressed into invasive carcinoma. All cases of DCIS are treated, whether mastectomies or lumpectomies with an excision margin of negative margins are used." - Anonymous Online Contributor
"Based on U.S. data, an estimated 2.4 million women are diagnosed annually, an increase of about 4.3% from 2003. Estimates based on death certificate data suggest a total of 18 million women in the U.S. suffer from breast cancer. Over 5.5 million women die from breast cancer each year." - Anonymous Online Contributor
"A core biopsy may be effective in patients with a breast mass who were assessed by ultrasound to have a solid mass which could not be palpated." - Anonymous Online Contributor
"Pregnancy and, to a lesser extent, family history represent two significant prognostic factors for survival of [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer) patients. These factors are also associated with a rapid development of carcinoma in situ and invasive carcinoma. Carcinoma in situ at the time of diagnosis is an excellent prognostic factor, but for many patients a diagnosis of carcinoma in situ and invasive carcinoma in such patients cannot be made earlier. Thus, it is important to identify additional factors that could prompt earlier cancer staging in selected patients." - Anonymous Online Contributor
"Survival rate for carcinoma with invasive ductal carcinoma is low, as shown in the following. The survival rates for mammary ductal carcinoma should be kept at a high level in order to increase life expectancy of patients." - Anonymous Online Contributor
"The use of core biopsy in conjunction with other treatments has improved the diagnostic rate. Core biopsy can provide information necessary for tailored treatment. In addition, core biopsy can be used as an alternative to the open surgical method for treatment of DCIS. Core biopsy should be used as a first-line method of diagnosis when all the criteria are fulfilled: palpable mass with ultrasound-defined lesion, negative margins at excision, and negativity of any hormone receptor status." - Anonymous Online Contributor
"In a recent study, findings of this population-based study support a referral pathway for clinical trials of MBC patients (and for the first time, breast cancer patients) that includes a thorough patient assessment to determine clinical eligibility for a trial. This pathway will provide a comprehensive care for patients, including an appropriate discussion of their treatment options and, especially, the opportunity of clinical trial participation in the decision-making process." - Anonymous Online Contributor
"Based on these developments, in our opinion, a large amount of high quality, and high cost material can be safely obtained in cases that are not eligible for a biopsy." - Anonymous Online Contributor